COMPLETE RESPONSE LETTER

Achieve gets CRL for cytisinicline over manufacturing, not efficacy or safety

The FDA cited third-party manufacturing and labeling issues, not the drug's clinical data, and Achieve plans to resubmit in Q4 2026 with a new manufacturing partner.

By AppliedXLJune 22, 2026Trial NCT04576949

Executive Summary

The FDA declined to approve cytisinicline for smoking cessation, but the rejection rests on manufacturing and labeling issues rather than on the Phase 3 clinical evidence.
The regulator identified no deficiencies in the drug's efficacy or safety data, leaving the two pivotal trials that supported the filing unchallenged.
Achieve has already lined up a new manufacturing partner and completed the technical steps needed to refile, pointing to a defined resubmission path rather than a return to the clinic.
A first new pharmacotherapy for smoking cessation in two decades remains unclaimed, and this delay keeps that opening unresolved against a field of drugs approved in other indications rather than this one.

The decision

Achieve Life Sciences, Inc. disclosed on June 22, 2026 that the FDA had issued a Complete Response Letter (a formal rejection requiring further action before reconsideration) for cytisinicline's NDA in adult smoking cessation. The letter followed a PDUFA target action date of June 20, 2026 that the FDA had set after accepting the application in September 2025. The company said it had anticipated receiving the CRL by that date, having disclosed on April 15, 2026 that it expected the outcome. Achieve+1

The deficiency

The FDA's cited deficiencies concern outstanding manufacturing-related observations from a cGMP inspection (a good-manufacturing-practice review) of a third-party manufacturing facility, plus final product labeling that was not completed by the action date. That facility received an Official Action Indicated classification, the FDA's most serious inspection finding short of a warning letter, for general cGMP matters not specific to cytisinicline. The agency identified no deficiencies regarding the drug's clinical efficacy or safety. Achieve CEO Andrew D. Goldberg said, "Our clinical data stands on its own: two successful Phase 3 trials and an open-label safety study,". Achieve

The underlying trials

The NDA drew on the Phase 3 ORCA-2 trial (NCT04576949), which enrolled 810 adult smokers and completed on December 23, 2021, testing 6- or 12-week cytisinicline courses against placebo alongside behavioral support. Achieve reported at the time that smokers on cytisinicline were up to eight times more likely to quit than those on placebo, though the release did not disclose absolute quit rates or statistical testing detail. A second pivotal trial, ORCA-3, and an open-label safety study, ORCA-OL, rounded out the program cited in the NDA. Posted results from ORCA-2 show serious adverse events in 3 of 270 placebo patients, 10 of 269 patients on the 6-week regimen, and 8 of 270 patients on the 12-week regimen. NCT04576949+1

The remediation path

Achieve said it has already completed the analytical method technology transfer to a new manufacturing partner, Adare Pharma Solutions, manufactured a first engineering batch, and qualified testing procedures at that site. The company intends to resubmit the NDA in the fourth quarter of 2026 naming Adare as its primary manufacturing partner, with potential FDA approval in the first half of 2027. The registered ORCA-2 trial itself carried protocol edits during enrollment, including an enrollment count that moved from 750 to 792 to a final 810 and a primary completion date that shifted from December 31, 2021 to January 31, 2022 before the trial completed on December 23, 2021. Achieve+1

The competitive field

No industry competitor shares cytisinicline's alpha4beta2 nicotinic acetylcholine receptor target and modality at Phase 3 or beyond in smoking cessation; the closest comparators, Pfizer's varenicline and Sanofi's dianicline, target the same receptor as approved or previously studied smoking-cessation agents but are not tracking toward this indication's next FDA decision. Cytisinicline also carries Breakthrough Therapy designation for a separate, not-yet-approved e-cigarette cessation indication, distinct from the adult combustible-smoking indication under review here. Against a field where no new pharmacotherapy for smoking cessation has been approved in FDA's own words a description Achieve itself invokes for two decades, a manufacturing-driven delay leaves that opening unclaimed rather than closing it. Achieve+1

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.